Clinical Trial Update: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 1]

View source ↗

Summary

Sanofi-sponsored multi-center open-label Phase 1b study in relapsed/refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Sanofi | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED